# Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01855230** · PHASE2 · COMPLETED · sponsor: **Asmacure Ltée** · enrollment: 14 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** ASM-024
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01855230
- **Lead sponsor:** Asmacure Ltée
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855230, "Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01855230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*